Dutasteride
Product Images NDC 51013-190

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Dutasteride (NDC 51013-190). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Puracap Pharmaceutical Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

90ct.jpg (90ct)

90ct.jpg (90ct)
Dutasteride Capsules 0.5 mg label from PuraCap Pharmaceutical LLC, showing 90 capsules per bottle. The label includes dosage instructions, warnings against use by women and children, storage conditions, and handling precautions. The product is manufactured by Humanwell PuraCap Pharmaceutical in Wuhan, China, with NDC 51013-190-09.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph showing mean change from baseline in AUA-SI scores over 24 months of treatment. Two lines represent placebo and dutasteride groups, with the dutasteride group showing a greater decrease in AUA-SI over time. Sample sizes for each group at different time points are also indicated.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph showing the percent of patients over 24 months of treatment for two groups: Placebo and Dutasteride. The graph includes cumulative number of events and number of patients at risk at multiple time points for each group, with the Placebo group displaying higher event percentages than the Dutasteride group over time.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A line graph showing the percentage of patients over 24 months of treatment in two groups: Placebo Group and Dutasteride Group. The y-axis represents percent of patients, and the x-axis represents months of treatment. The graph includes cumulative event counts and numbers at risk for both groups at 0, 6, 12, 18, and 24 months.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
Bar chart showing mean percent change from baseline over months of treatment comparing Dutasteride and Placebo groups. The x-axis represents months (0, 1, 3, 6, 12, 24), and the y-axis shows percent change, ranging from 0 to -30. Dutasteride bars show a larger negative percent change at each time point compared to Placebo.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A line graph illustrating the mean change from baseline in mL/sec over 24 months of treatment comparing Dutasteride and placebo. The x-axis represents months of treatment from 0 to 24, and the y-axis shows the mean change from baseline in flow rate (mL/sec). Dutasteride shows a greater increase over time compared to placebo, with sample sizes noted for each treatment group at different time points.*
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
A line graph showing the mean change from baseline in IPSS over 48 months of treatment for Dutasteride plus tamsulosin, Dutasteride 0.5 mg, and Tamsulosin 0.4 mg groups. The graph compares symptom changes across these three treatments over time.*
FDA Label Image

Figure-7 (Figure 7)

Figure-7 (Figure 7)
A line graph depicting mean change from baseline urine flow rate (mL/sec) over 24 months of treatment for three groups: Dutasteride with tamsulosin, Dutasteride 0.5 mg, and Tamsulosin 0.4 mg. The graph compares treatment effects in a sample size ranging from approximately 1,388 to 1,519 across groups and time points.*
FDA Label Image

Structural-formula (Structural Formula)

Structural-formula (Structural Formula)
Chemical structure diagram of Dutasteride, showing its steroidal core with attached trifluoromethyl-substituted phenyl group and amide functionalities, consistent with its known molecular configuration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.